Former Executive Chairman, Current Chairman of the Board · Niagen Bioscience, Inc. (NAGE)

Frank Jaksch Jr.

A named executive officer of Niagen Bioscience in every fiscal year CompBrief holds from FY2017 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$482,354

Salary $223,984Stock awards $0

FY2021: $694,559

4th of 4 named executive officers at Niagen Bioscience by FY2022 total.

4 named officers on file for Niagen Bioscience, FY2022

Frank Jaksch Jr.’s pay file — $29

  • 6 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Niagen Bioscience’s whole pay program stands against its peers

  • Niagen Bioscience’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on NAGE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2023 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Frank Jaksch Jr.’s full pay file as a PDF — free

More than this page: up to 10 years of Frank’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Frank Jaksch Jr. compensation by year

Niagen Bioscience Summary Compensation Table · all 6 fiscal years held
In US dollars, as Niagen Bioscience reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019FY2020FY2021FY2022
Salary$370,000$370,000$378,111$398,758$381,100$223,984
Bonus$75,480$100,000$120,938$0$0$0
Stock awards$0$0$0$0$0$0
Option awards$0$188,960$129,329$142,253$190,256$190,080
Non-equity incentive$0$0$0$184,392$113,778$0
Pension and deferred compensation$0$0$0$0$0$0
All other$8,100$8,650$8,400$9,275$9,425$68,289
Total$453,580$667,610$636,778$734,678$694,559$482,354

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Niagen Bioscience, Inc. DEF 14A filed April 28, 2023, accession 0001628280-23-014158, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Niagen Bioscience, Inc. filed document, accession 0001628280-23-014158. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2023.

$454K
$668K
$637K
$735K
$695K
$482K
FY17
FY18
FY19
FY20
FY21
FY22
SalaryBonusNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
PSU166,668$280,002—
Option4,114—$3.27
Option10,447—$11.83
Option107,805—$2.67

Per the Outstanding Equity Awards at Fiscal Year-End table in Niagen Bioscience, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

6 Form 4 lines since the FY2022 proxy (filed April 28, 2023)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-24Grant or award derivative—31,746$0.0031,746
2025-06-24Grant or award derivative—20,000$0.0020,000
2024-12-13Exercise or conversion—50,001$3.66281,340
2024-12-13Sale—37,161$6.19244,179
2024-12-13Exercise or conversion derivative—50,001$0.000
2024-06-20Grant or award derivative—20,000$0.0020,000

The 6 most recent of 6 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Niagen Bioscience’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Robert FriedChief Executive Officer$1,158,850
Brianna GerberChief Financial Officer$842,384
Kevin FarrFormer Chief Financial Officer$839,537
Frank Jaksch Jr. · this pageFormer Executive Chairman, Current Chairman of the Board$482,354

Board service

Niagen Bioscience board · FY2023–FY2025
Director compensation in US dollars, as Niagen Bioscience reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$70,000—$198,076$0$268,076
FY2024$70,000$0$36,319$0$106,319
FY2023$70,000—$22,311$0$92,311

Each year as the company reported it in Niagen Bioscience's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Niagen Bioscience pays directors a $40,000 cash retainer and $20,000 in Options. As stated in Niagen Bioscience's FY2025 proxy.

The full Niagen Bioscience compensation record

free company brief

This page is one person within Niagen Bioscience's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Niagen Bioscience's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Frank Jaksch Jr.'s compensation dossier · One-time report. No refunds.